<DOC>
	<DOCNO>NCT01676818</DOCNO>
	<brief_summary>This phase II trial study well eribulin mesylate work treat patient advanced recurrent cervical cancer . Drugs use chemotherapy , eribulin mesylate , work different way stop growth tumor cell , either kill cell stop divide</brief_summary>
	<brief_title>Eribulin Mesylate Treating Patients With Advanced Recurrent Cervical Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate activity eribulin ( eribulin mesylate ) management advanced recurrent cervical cancer ( progression-free survival [ PFS ] . SECONDARY OBJECTIVES : I . To describe toxicity profile eribulin patient advance recurrent cervical cancer . II . To estimate survival patient advance recurrent cervical cancer treat eribulin . III . To evaluate potential correlative study predictive prognostic maker patient population ( glucose-regulated protein 78 [ GRP78 ] level tissue blood , tumor protein p53 [ p53 ] expression , apoptosis terminal deoxynucleotidyl transferase dUTP nick end label [ TUNEL ] assay , apoptosis-related protein B-cell lymphoma 2 [ Bcl-2 ] Bcl2-associated X protein [ Bax ] use immunohistochemistry [ IHC ] , proliferation Ki-67 IHC , expression level microtubule-associated variable , include tau protein , total alpha- beta-tubulin , class II-IV beta-tubulin isotope IHC . OUTLINE : Patients receive eribulin mesylate 1.4 mg/m2 intravenously ( IV ) bolus 2-5 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>Histologically confirm diagnosis invasive cervical cancer Measurable disease 01 prior chemotherapy regimens recurrent advanced disease ; platinum base chemotherapy administer radiation sensitizer agent allow count prior therapy Absolute granulocyte count ( AGC ) &gt; = 1,500 Platelet &gt; = 100,000 Serum creatinine &lt; 2.0 mg/dl Bilirubin = &lt; 1.5 time upper limit normal range ( ULN ) Alkaline phosphatase = &lt; 3 x ULN ( case liver metastasis , = &lt; 5 x ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) = &lt; 3 x ULN ( case liver metastasis , = &lt; 5 x ULN ) Peripheral neuropathy grade 02 Recovery chemotherapy radiationrelated toxicity grade = &lt; 1 , except alopecia peripheral neuropathy Performance status 02 Signed inform consent Prior treatment eribulin Chemotherapy , radiation , biological target therapy within 3 week Hormonal therapy within 1 week Any investigational drug within 4 week Known brain metastasis , unless previously treat asymptomatic 3 month progressive size number 3 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>